• Sentimag Gen Ad x
  • US KEY Keytruda ADT HCP Update Patient Candidate Banner Ads MT Branded Static x
  • Surgical Oncology Insight Banner Ad x

ADVERTISEMENT

Global Header

Young Investigator Award

Thank you to those who applied for the 2024 Young Investigator Awards. Applications are now closed for 2024 Funding. 

The Young Investigator Award promotes and recognizes clinical and translational research that advances innovative ideas and concepts designed to improve health outcomes through advances in the delivery of cancer-related care. This year, two awards will be given for up to $25,000 each for one year, beginning April 1 of the award year and concluding March 31 of the following year.

Two Young Investigator Awards will be made again this year: one traditional award and one dedicated to a specific topic.

SSO is pleased to offer a second, topic-specific SSO Young Investigator Award supported by a grant from the Appendix Cancer Pseudomyxoma Peritonei Research Foundation. Proposals related to appendix cancer, pseudomyxoma peritonei, peritoneal surface malignancies/peritoneal carcinomatosis (as related to appendix cancer and/or pseudomyxoma peritonei), and/or HIPEC as a treatment for appendix cancer/pseudomyxoma peritonei will be accepted.

Eligibility
Applicants must:
  • Hold DO, MD, or MD/PhD degrees
  • Be surgical oncologists within five (5) years of completion of fellowship or related training.
  • Be an SSO U.S. member for at least six (6) months prior to application submission to be eligible for an award.
  • Proposed research cannot have received other competitive, peer-reviewed funding for the project.
  • Applicant must be considered an early-stage investigator by NIH criteria.
Young Investigator Award
Any topic
Supported by SSO
 
Global Header
 
Young Investigator Award-Appendix Cancer, Pseudomyxoma Peritonei (PMP)
and Related Cancers
Proposals related to appendix cancer, pseudomyxoma peritonei, peritoneal surface malignancies/peritoneal carcinomatosis (as related to appendix cancer and/or pseudomyxoma peritonei) and/or HIPEC generally as a treatment for appendix cancer/pseudomyxoma peritonei
 
Supported by a grant from: 
Horizontal ACPMP Logo
 
 
Please contact Pam Hayden, Director, Quality and Research Programs, with any questions at pamhayden@surgonc.org.
Navigate
Scroll to Top